A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Verastem, Inc.
AstraZeneca
Seagen Inc.
Seagen Inc.
Pfizer
M.D. Anderson Cancer Center
Jiangsu Cancer Institute & Hospital
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Genmab
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Actuate Therapeutics Inc.
NRG Oncology
Revolution Medicines, Inc.